Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia : results from the EVOLUTION European registry
(2021) In World Journal of Urology 39(7). p.2661-2667- Abstract
Background: To use the European Association of Urology Research Foundation (EAURF) registry data to determine the proportion of contemporary Lower Urinary Tract Symptoms associated with Benign Prostatic Enlargement (LUTS/BPE) patients prescribed phytotherapy, and to determine their subjective quality of life and clinical progression responses. Methods: This was a prospective multicenter multinational observational registry study, conducted over 2 years. Men ≥ 50 years seeking LUTS/BPE were divided at baseline into two cohorts, presently/recently untreated patients (PUP) commencing pharmacotherapy at baseline and presently/recently treated patients (c-PTP) continuing previously received pharmacotherapy, with 24-month follow-up (FU).... (More)
Background: To use the European Association of Urology Research Foundation (EAURF) registry data to determine the proportion of contemporary Lower Urinary Tract Symptoms associated with Benign Prostatic Enlargement (LUTS/BPE) patients prescribed phytotherapy, and to determine their subjective quality of life and clinical progression responses. Methods: This was a prospective multicenter multinational observational registry study, conducted over 2 years. Men ≥ 50 years seeking LUTS/BPE were divided at baseline into two cohorts, presently/recently untreated patients (PUP) commencing pharmacotherapy at baseline and presently/recently treated patients (c-PTP) continuing previously received pharmacotherapy, with 24-month follow-up (FU). Results: Overall, 2175 patients were enrolled with 1838 analyzed. Of the PUP cohort (n = 575), 92 (16%) received phytotherapy and 65 (71%, n = 65/92) completed 24-month FU, with France prescribing 34% (n = 30/89) the highest proportion of phytotherapy among all LUTS/BPE medications. In the c-PTP group (n = 1263), only 69 (5%) patients were using phytotherapy, falling to n = 35/69 (51%) at 24-month FU (highest in France 20% (n = 43/210)). Though defined disease progression occurred in ≤ 20%, with only 1% proceeding to surgical intervention, in both groups, clinically meaningful improvement was lower and symptom persistence was higher in PUP but similar in the treated (c-PTP) patients on phytotherapy compared to the other LUTS/BPE medication. Conclusion: Low heterogeneous prescribing rates for phytotherapy were reported in both PUP and c-PTP cohorts over the 24-month FU. Although phytotherapy led to subjective improvements, healthcare practitioners should prescribe them with caution until higher quality evidence and guideline recommendations supporting its use are available.
(Less)
- author
- Bhatt, Nikita R. ; Davis, Niall F. ; Witjes, W. P. ; Bjartell, A. LU ; Caris, C. ; Patel, A. ; de la Taille, A. ; Speakman, Mark ; Martínez-Piñeiro, Luis and Tubaro, A.
- organization
- publishing date
- 2021-07-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Benign prostatic enlargement, Guidelines, Medical treatment, Plant extracts, Serona repens
- in
- World Journal of Urology
- volume
- 39
- issue
- 7
- pages
- 7 pages
- publisher
- Springer
- external identifiers
-
- pmid:33067725
- scopus:85092564350
- ISSN
- 0724-4983
- DOI
- 10.1007/s00345-020-03480-w
- language
- English
- LU publication?
- yes
- id
- 9ebe2860-6858-4d60-afe0-709b92eb53c8
- date added to LUP
- 2020-11-12 10:38:57
- date last changed
- 2024-05-29 22:51:52
@article{9ebe2860-6858-4d60-afe0-709b92eb53c8,
abstract = {{<p>Background: To use the European Association of Urology Research Foundation (EAURF) registry data to determine the proportion of contemporary Lower Urinary Tract Symptoms associated with Benign Prostatic Enlargement (LUTS/BPE) patients prescribed phytotherapy, and to determine their subjective quality of life and clinical progression responses. Methods: This was a prospective multicenter multinational observational registry study, conducted over 2 years. Men ≥ 50 years seeking LUTS/BPE were divided at baseline into two cohorts, presently/recently untreated patients (PUP) commencing pharmacotherapy at baseline and presently/recently treated patients (c-PTP) continuing previously received pharmacotherapy, with 24-month follow-up (FU). Results: Overall, 2175 patients were enrolled with 1838 analyzed. Of the PUP cohort (n = 575), 92 (16%) received phytotherapy and 65 (71%, n = 65/92) completed 24-month FU, with France prescribing 34% (n = 30/89) the highest proportion of phytotherapy among all LUTS/BPE medications. In the c-PTP group (n = 1263), only 69 (5%) patients were using phytotherapy, falling to n = 35/69 (51%) at 24-month FU (highest in France 20% (n = 43/210)). Though defined disease progression occurred in ≤ 20%, with only 1% proceeding to surgical intervention, in both groups, clinically meaningful improvement was lower and symptom persistence was higher in PUP but similar in the treated (c-PTP) patients on phytotherapy compared to the other LUTS/BPE medication. Conclusion: Low heterogeneous prescribing rates for phytotherapy were reported in both PUP and c-PTP cohorts over the 24-month FU. Although phytotherapy led to subjective improvements, healthcare practitioners should prescribe them with caution until higher quality evidence and guideline recommendations supporting its use are available.</p>}},
author = {{Bhatt, Nikita R. and Davis, Niall F. and Witjes, W. P. and Bjartell, A. and Caris, C. and Patel, A. and de la Taille, A. and Speakman, Mark and Martínez-Piñeiro, Luis and Tubaro, A.}},
issn = {{0724-4983}},
keywords = {{Benign prostatic enlargement; Guidelines; Medical treatment; Plant extracts; Serona repens}},
language = {{eng}},
month = {{07}},
number = {{7}},
pages = {{2661--2667}},
publisher = {{Springer}},
series = {{World Journal of Urology}},
title = {{Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia : results from the EVOLUTION European registry}},
url = {{http://dx.doi.org/10.1007/s00345-020-03480-w}},
doi = {{10.1007/s00345-020-03480-w}},
volume = {{39}},
year = {{2021}},
}